Another FDA Warning Letter for inadequate CAPAs
Recommendation
4/5 December 2024
Berlin, Germany
A CAPA Workshop on Successful Failure Investigation
Register now for ECA's GMP Newsletter
Deviations and CAPAs are still hotly debated topics in GMP inspections. This is shown once again by a recent Warning Letter issued by the U.S. Food and Drug Administration (FDA).
In this Warning Letter, the FDA tells an Indian Glenmark site that it failed to investigate "unexplained discrepancy or failure". In particular, FDA found that investigations to identify appropriate root causes were inadequate and that the company failed to implement sustainable corrective action and preventive action (CAPA).
Observations were made in the following systems:
Complaint Handling:
Over the last years, Glenmark received multiple complaints of grittiness for a topical cream. This has been an ongoing formulation issue since 2010 and was a deficiency also cited in previous inspections. The product was reformulated, but the company failed to provide "sufficient data to demonstrate the robustness of the new formulation".
Furthermore, various consumer complaints associated with punctures, cracks, and holes in various container and closure systems were not adequately investigated. Glenmark stated that "the complaint rate is insignificant" and closed most of the complaints, without corrective or preventive actions.
Temperature Excursions
According to the Warning Letter, the company "failed to adequately investigate multiple temperature excursions that occurred during shipping" of drug products. The FDA criticized that investigations performed did not include timely actions to prevent recurrence of the temperature excursions.
Also these deficiencies have been cited during a previous inspection. An adequate risk assessment for products exposed to temperatures outside the labeled storage conditions was not provided. New shipping practices to protect the products "were not implemented in a timely manner".
OOS Handling
After confirmed OOS test results, respective batches were ultimately rejected. However, investigations into these failures "did not determine an appropriate root cause and ensure effective CAPA".
The FDA now expects a "comprehensive, independent assessment" of the system "for investigating deviations, discrepancies, complaints, OOS results, and failures" including a "detailed action plan to remediate this system".
For more details, please see the FDA's Warning Letter to Glenmark Pharmaceuticals Limited.
Related GMP News
30.10.2024From missing Analysis to Brand Protection Violations - FDA Warning Letter to Canadian Manufacturer
23.10.2024Root Cause Analysis: What can be found in FDA Warning Letters?
23.10.2024Do you want to host FDA Staff? FDA announces Experiential Learning Site Visit Program
09.10.2024Management circumvents Quality Department in Deviation Classification - FDA Warning Letter
09.10.2024Despite MRA: Why does the FDA inspect so frequently in the EU?
02.10.2024Swissmedic launched own GMDP Database